Challenge and rechallenge: Drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis

Pharmacotherapy

Volumn 25, Issue 8, 2005, Pages 1147-1150

  Castelli, Emily E ^a   Culley, Colleen M ^a   Fink, Mitchell P ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Drotrecogin alfa (activated); Partial thromboplastin time; Sepsis

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; CEFOTETAN; DROTRECOGIN; FIBRINOLYTIC AGENT; HEMOGLOBIN; HEPARIN; NORADRENALIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; RECOMBINANT PROTEIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADJUVANT THERAPY; ADULT; AGED; ANTIBIOTIC THERAPY; ANTICOAGULATION; ARTIFICIAL VENTILATION; BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; CASE REPORT; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG WITHDRAWAL; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTESTINE ISCHEMIA; LAPAROTOMY; MEDICAL RECORD; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PATIENT MONITORING; PROTHROMBIN TIME; PROVOCATION TEST; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SEPTIC SHOCK; SMALL INTESTINE RESECTION; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; APACHE; FEMALE; HUMANS; INTESTINAL OBSTRUCTION; LAPAROTOMY; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTEIN C; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEPSIS;

EID: 23244462435     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.8.1147     Document Type: Review

References (17)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
3. Eli Lilly and Company. Xigris (drotrecogin alfa [activated]) package insert. Indianapolis, IN; 2003.
4. Dellinger RP. Inflammation and coagulation: implications for the septic patient. Clin Infect Dis 2003;36:1259-65.
5. Dhainaut JF, Van SB, Cariou A, Mira JP. Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 2002;30:S318-24.
6. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
7. Castelli EE, Culley CM, Fink MP. Incidence of coagulopathy, bleeding and mortality in drotrecogin alfa (activated)-treated patients [abstr]. Crit Care Med 2003;31:A122.
8. Bernard GR, Vincent JL, Laterre PR, et al, for the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
9. Matthay MA. Severe sepsis: a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001;344:759-62.
10. Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003;31(suppl):S85-93.
11. Evans HL, Milburn ML, Calloway T, et al. Treating medical and surgical patients with activated protein C: a preliminary comparison [abstr]. Crit Care 2003;7(suppl 2):P022.
12. Higgins T, Steingrub J, Tereso G, et al. Recombinant activated protein C in sepsis: a single center's experience [abstr]. Crit Care Med 2002;30(suppl 12):A103.
13. Quap CW, Tran JI, Jackson A, et al. The use of recombinant human activated protein C, (rhAPC, drotrecogin alfa [activated]) in the management of patients with sepsis in the community hospital setting [abstr]. Crit Care Med 2002;30(suppl 12):A103.
14. Nguyen NQ, Jaresko GS, Savani D, et al. Clinical outcomes and adverse effects of patients treated with drotrecogin alfa [abstr]. Crit Care Med 2002;30(suppl 12):A104.
15. Swerlin A, Conty W, McClusky C, et al. Initial experience with drotrecogin alfa (activated) in two large tertiary care facilities [abstr]. Crit Care Med 2002;30(suppl 12):A104.
16. Dhainaut JF, Van SB, Margolis BD, et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003;90:642-53.
17. de Pont AC, Bouman CS, de Jonge E, Vroom MB, Buller HR, Levi M. Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis [letter]. Intensive Care Med 2003;29:1205.